UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
July 4, 2016
Date of Report (Date of earliest event reported)
MESA LABORATORIES, INC.
(Exact name of registrant as specified in its charter)
Commission File Number: 0-11740
|
COLORADO |
|
84-0872291 |
|
12100 WEST SIXTH AVENUE, LAKEWOOD, COLORADO |
|
80228 |
Registrant’s telephone number, including area code: (303) 987-8000
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
|_| |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|_| |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|_| |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|_| |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
ITEM 8.01 OTHER EVENTS
In July 2016, Mesa Laboratories, Inc. (the “Company”) today announced the acquisition of certain assets and liabilities of HANSAmed Limited (“HANSAmed”) by the Company’s subsidiary, Mesa Canada, Inc. (“Mesa Canada”). HANSAmed was a distributor of the Company’s biological indicator (“BI”) products.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS
|
(d) |
Exhibits: |
| 99.1 Press release dated July 5, 2016. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
DATE: July 5, 2016 |
|
|
Mesa Laboratories, Inc. (Registrant) | |
| /s/ John J. Sullivan | ||||
| BY: | John J. Sullivan, | |||
| President and Chief Executive Officer |